We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Immediate Diagnosis Provided at POC for Cardiac Patients

By LabMedica International staff writers
Posted on 12 Oct 2009
A new biochip analyzer will help save cardiac patients lives by providing immediate diagnosis at the point of care (POC). The technology is based on the concept of using a biochip as a reaction platform with multiple specific ligands (antibodies and antigens) attached at pre-defined sites on the surface.

The Evidence MultiStat biochip analyzer is a product of Randox (Crumlin, UK). In addition to cardiac tests, it offers arrays for stroke, metabolic syndrome, cancer, fertility disorders, thyroid disorders, synthetic steroids, and drugs of abuse. The Evidence MutiStat belongs to a family of flexible and reliable immunoassay analyzers. The largest member of the family is the Evidence, which has an output of 1,400 tests per hour.

The MutiStat system is suitable for emergency departments, cardiac units, doctor's surgeries, forensic units, rehabilitation units, and employee drug screening centers. The technology offers fully automated pipetting, incubation, washing, imaging, and report generation. This, together with a user-friendly touch screen and Windows-based software, enables the MultiStat to be used by nontechnical staff with little or no training.

The test menu can work with a wide range of sample matrix including urine and serum--plasma and whole blood are currently in development. The cardiac arrays include creatinine kinase-MB (CK-MB), fatty acid binding protein (FABP), myoglobin, and cardiac troponin. The drugs of abuse arrays include multiple analytes such as amphetamine, barbiturates, benzadiazepine, cannabinoids, and cocaine.

Cardiovascular disease is a progressive and complicated condition, covering a range of symptoms and biochemical processes that vary according to the patient. Multiple markers are therefore required to provide accurate diagnoses. The new Randox technology benefits patients with chest pains by rapidly identifying risk and enabling accurate clinical decisions.

Randox is a diagnostics company that develops, manufactures, and markets clinical diagnostic products worldwide. Its core products include biochip array technology; clinical chemistry analyzers and reagents; quality controls; recombinant proteins and antibodies.

Related Links:

Randox



Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test
Automated Blood Typing System
IH-500 NEXT
New
Toxoplasma Gondii Test
Toxo IgG ELISA Kit
New
Histamine ELISA
Histamine ELISA

Latest Immunology News

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Advanced Imaging Method Maps Immune Cell Connections to Predict Cancer Patients Survival

Computational Tool Predicts Immunotherapy Outcomes for Metastatic Breast Cancer Patients